How ValueAct Shook Off Its Big Loss from Valeant

January 06, 2017   Stephen Taub

The hedge fund firm, headed by Jeff Ubben, did not suffer the same fate as other major shareholders of the ailing pharmaceutical concern.

It is no secret that the shares of Valeant Pharmaceuticals International have destroyed the performance of a number of hedge funds. Just look at the double-digit losses suffered by its two biggest shareholders, Pershing Square Capital Management and Paulson & …


Subscribers have unlimited access to all online content inc rankings. Start your subscription today - click on the button below.

Subscribe now

Free trial

Taking a free trial will give you access to online content one week (excludes research & rankings). Start your trial today.

Free Trial

Latest Poll

How will hedge funds finish 2017?

 - 72%
 - 11%
 - 17%

View previous results